Equity Field Notes from temporal sources

[DanWebzster]

XENE has a multi-faced pipeline that focuses primarily on Epilepsy and secondarily on Pain.

2021 will likely bring a significant milestone payment from NBIX and an H-1 Ph2B POC readout in Adult Focal Epilepsy.

Q2/20 XENE reported 202.8M in cash and the initiation of a 100M ATM. One criticism of this public company is that has been a wanton capraiser/diluter.

To me this is a biotech with a pipeline that is vulnerable to setback. Epilepsy is a difficult condition to treat. As an example, Potiga, a competing treatment from GSK, has earned a black box warning.

At my level of understanding of this pipeline, I cannot take on the risk of holding this stock overnight. After a successful 2021 Ph2B POC, I may consider daytrading or trading a day-2 continuation.